https://www.selleckchem.com/products/rmc-6236.html
Therefore, sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists should be considered for the management of people with preserved insulin production being at high cardiovascular risk. The risk of diabetic ketoacidosis with SGLT2is requires increased vigilance by treating physicians. Individualisation, preservation of beta-cell mass and function and cardiorenal protection are the new challenges in LADA therapy. Individualisation, preservation of beta-cell mass and function and cardiorenal pro
Like
Comment
Share
